CSPC Pharmaceutical Signs Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra in China

 CSPC Pharmaceutical Signs Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra in China

CSPC Pharmaceutical Signs Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra in China

Shots:

  • Verastem will receive an upfront of $15M with up to $30M for development milestones, additional sales milestones and double-digit royalties on net sales of Copiktra (duvelisib)
  • CSPC to get exclusive development and commercialization rights of Copiktra in China and will also assist Verastem in R&D activities globally on cost sharing basis
  • Copiktra is an oral inhibitor of PI3Ki (phosphoinositide 3-kinase), first approved dual inhibitor of PI3K-delta and PI3K-gamma and received approval from FDA for the treatment of r/r chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies

Click here to read full press release/ article | Ref: Verastem Oncology | Image: Wall Street

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post